本帖最后由 老马 于 2012-1-13 21:20 编辑
( x* m' v) ]6 o, z5 R6 Y) ]0 n+ h& P4 p& ]' F
爱必妥和阿瓦斯丁的比较1 l4 J8 Y5 M% H$ g! _1 v* h1 J. S
* K' e" z7 q" M% r6 R5 p# y7 ?http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ l1 B, v2 r/ N! K0 V4 G
' o3 W) n3 b2 v$ t
, j9 X' h( }) r3 I [
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 w0 ]5 i- M( Z( L' k' Z8 U
==================================================
, A1 M7 {- G+ O& VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! {2 y9 M6 }% l% R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 e1 w: N, z5 U( ?Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* o" l: B) K2 z1 l
|